Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaPture: Cabozantinib in HCC Refractory to PD-1 Inhibitors
NCT04767906Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Dec 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Leipzig University. Started Dec 2021; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04767906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767906.